<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p186" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_186{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_186{left:306px;bottom:30px;}
#t3_186{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_186{left:346px;bottom:30px;}
#t5_186{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_186{left:517px;bottom:30px;}
#t7_186{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_186{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_186{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_186{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_186{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:-1.06px;}
#tc_186{left:572px;bottom:785px;letter-spacing:-0.01px;}
#td_186{left:35px;bottom:754px;letter-spacing:0.27px;}
#te_186{left:73px;bottom:754px;letter-spacing:0.21px;word-spacing:-1.25px;}
#tf_186{left:288px;bottom:754px;letter-spacing:-0.31px;}
#tg_186{left:320px;bottom:754px;letter-spacing:0.12px;word-spacing:-1.17px;}
#th_186{left:577px;bottom:754px;letter-spacing:-0.11px;}
#ti_186{left:35px;bottom:731px;letter-spacing:0.11px;word-spacing:-1.15px;}
#tj_186{left:35px;bottom:707px;letter-spacing:0.16px;word-spacing:-0.1px;}
#tk_186{left:35px;bottom:684px;letter-spacing:0.03px;word-spacing:-0.47px;}
#tl_186{left:138px;bottom:692px;letter-spacing:-0.01px;}
#tm_186{left:161px;bottom:684px;letter-spacing:0.1px;word-spacing:0.09px;}
#tn_186{left:35px;bottom:661px;letter-spacing:0.18px;word-spacing:-0.24px;}
#to_186{left:35px;bottom:638px;letter-spacing:0.14px;word-spacing:0.05px;}
#tp_186{left:35px;bottom:614px;letter-spacing:0.11px;word-spacing:0.08px;}
#tq_186{left:165px;bottom:622px;letter-spacing:-0.01px;}
#tr_186{left:188px;bottom:614px;letter-spacing:0.03px;word-spacing:0.15px;}
#ts_186{left:35px;bottom:591px;letter-spacing:0.07px;word-spacing:-0.7px;}
#tt_186{left:166px;bottom:591px;}
#tu_186{left:181px;bottom:591px;letter-spacing:0.07px;word-spacing:-0.62px;}
#tv_186{left:440px;bottom:591px;}
#tw_186{left:455px;bottom:591px;letter-spacing:0.24px;word-spacing:-0.47px;}
#tx_186{left:35px;bottom:568px;letter-spacing:0.11px;word-spacing:0.08px;}
#ty_186{left:35px;bottom:545px;letter-spacing:0.08px;word-spacing:-1.13px;}
#tz_186{left:317px;bottom:552px;letter-spacing:-0.01px;}
#t10_186{left:340px;bottom:545px;letter-spacing:0.11px;word-spacing:0.07px;}
#t11_186{left:35px;bottom:522px;letter-spacing:0.08px;word-spacing:-0.97px;}
#t12_186{left:35px;bottom:498px;letter-spacing:0.15px;word-spacing:0.04px;}
#t13_186{left:369px;bottom:506px;letter-spacing:-0.01px;}
#t14_186{left:392px;bottom:498px;letter-spacing:0.1px;word-spacing:0.09px;}
#t15_186{left:35px;bottom:475px;letter-spacing:0.07px;word-spacing:0.12px;}
#t16_186{left:35px;bottom:452px;letter-spacing:0.06px;word-spacing:-0.33px;}
#t17_186{left:35px;bottom:430px;letter-spacing:0.14px;word-spacing:0.05px;}
#t18_186{left:35px;bottom:407px;letter-spacing:0.04px;word-spacing:0.15px;}
#t19_186{left:35px;bottom:383px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1a_186{left:35px;bottom:360px;letter-spacing:0.09px;word-spacing:0.09px;}
#t1b_186{left:35px;bottom:337px;letter-spacing:0.09px;word-spacing:-0.77px;}
#t1c_186{left:35px;bottom:314px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1d_186{left:125px;bottom:321px;letter-spacing:-0.01px;}
#t1e_186{left:148px;bottom:314px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1f_186{left:35px;bottom:291px;letter-spacing:0.03px;word-spacing:0.15px;}
#t1g_186{left:35px;bottom:250px;letter-spacing:0.11px;word-spacing:-0.88px;}
#t1h_186{left:35px;bottom:227px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1i_186{left:35px;bottom:204px;letter-spacing:0.13px;word-spacing:0.05px;}
#t1j_186{left:35px;bottom:181px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t1k_186{left:35px;bottom:157px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1l_186{left:35px;bottom:134px;letter-spacing:0.03px;word-spacing:0.16px;}
#t1m_186{left:35px;bottom:111px;letter-spacing:0.04px;word-spacing:0.15px;}
#t1n_186{left:618px;bottom:777px;letter-spacing:0.02px;word-spacing:0.16px;}
#t1o_186{left:618px;bottom:754px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1p_186{left:1003px;bottom:754px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1q_186{left:618px;bottom:731px;letter-spacing:0.29px;}
#t1r_186{left:675px;bottom:731px;letter-spacing:-0.31px;}
#t1s_186{left:706px;bottom:731px;letter-spacing:0.17px;word-spacing:-1.21px;}
#t1t_186{left:963px;bottom:731px;letter-spacing:0.19px;}
#t1u_186{left:618px;bottom:707px;letter-spacing:0.12px;word-spacing:-0.35px;}
#t1v_186{left:618px;bottom:684px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1w_186{left:618px;bottom:661px;letter-spacing:0.15px;word-spacing:0.03px;}
#t1x_186{left:755px;bottom:668px;letter-spacing:0.1px;}
#t1y_186{left:801px;bottom:661px;letter-spacing:0.01px;word-spacing:0.17px;}
#t1z_186{left:618px;bottom:638px;letter-spacing:0.14px;word-spacing:0.05px;}
#t20_186{left:618px;bottom:614px;letter-spacing:0.08px;word-spacing:0.1px;}
#t21_186{left:618px;bottom:591px;letter-spacing:0.12px;word-spacing:-1.16px;}
#t22_186{left:983px;bottom:599px;}
#t23_186{left:994px;bottom:591px;letter-spacing:0.04px;word-spacing:0.15px;}
#t24_186{left:618px;bottom:568px;letter-spacing:0.1px;word-spacing:0.08px;}
#t25_186{left:618px;bottom:545px;letter-spacing:0.08px;word-spacing:-1.13px;}
#t26_186{left:618px;bottom:522px;letter-spacing:0.03px;word-spacing:0.04px;}
#t27_186{left:618px;bottom:498px;letter-spacing:0.11px;word-spacing:0.08px;}
#t28_186{left:618px;bottom:475px;letter-spacing:0.15px;word-spacing:0.04px;}
#t29_186{left:618px;bottom:452px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t2a_186{left:618px;bottom:430px;word-spacing:-0.59px;}
#t2b_186{left:618px;bottom:407px;letter-spacing:0.19px;}
#t2c_186{left:618px;bottom:383px;letter-spacing:0.1px;word-spacing:-1.15px;}
#t2d_186{left:618px;bottom:360px;letter-spacing:0.04px;word-spacing:-0.54px;}
#t2e_186{left:618px;bottom:337px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2f_186{left:618px;bottom:314px;letter-spacing:0.16px;word-spacing:-0.46px;}
#t2g_186{left:618px;bottom:291px;letter-spacing:0.13px;word-spacing:-0.32px;}
#t2h_186{left:618px;bottom:267px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2i_186{left:809px;bottom:275px;letter-spacing:-0.01px;}
#t2j_186{left:832px;bottom:267px;letter-spacing:0.28px;word-spacing:-0.09px;}
#t2k_186{left:618px;bottom:244px;letter-spacing:0.07px;word-spacing:-0.71px;}
#t2l_186{left:618px;bottom:221px;letter-spacing:0.02px;word-spacing:-1.07px;}
#t2m_186{left:618px;bottom:198px;letter-spacing:0.11px;word-spacing:0.09px;}
#t2n_186{left:827px;bottom:205px;letter-spacing:-0.01px;}
#t2o_186{left:851px;bottom:198px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2p_186{left:618px;bottom:174px;letter-spacing:0.07px;word-spacing:0.12px;}
#t2q_186{left:618px;bottom:151px;letter-spacing:0.11px;word-spacing:0.07px;}
#t2r_186{left:618px;bottom:111px;letter-spacing:0.15px;word-spacing:-0.08px;}
#t2s_186{left:618px;bottom:88px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2t_186{left:618px;bottom:64px;letter-spacing:0.21px;word-spacing:-1.25px;}
#t2u_186{left:834px;bottom:64px;letter-spacing:-0.31px;}
#t2v_186{left:867px;bottom:64px;letter-spacing:0.21px;word-spacing:-0.03px;}
#t2w_186{left:1131px;bottom:64px;letter-spacing:0.17px;word-spacing:0.01px;}
#t2x_186{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_186{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_186{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_186{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_186{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_186{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_186{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_186{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_186{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts186" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg186Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg186" style="-webkit-user-select: none;"><object width="1210" height="935" data="186/186.svg" type="image/svg+xml" id="pdf186" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_186" class="t s0_186">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_186" class="t s1_186">© </span>
<span id="t3_186" class="t s0_186">(NCCN </span>
<span id="t4_186" class="t s1_186">© </span>
<span id="t5_186" class="t s0_186">), All rights reserved. NCCN Guidelines </span>
<span id="t6_186" class="t s1_186">® </span>
<span id="t7_186" class="t s0_186">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_186" class="t s2_186">NCCN Guidelines Version 4.2024 </span>
<span id="t9_186" class="t s2_186">Head and Neck Cancers </span>
<span id="ta_186" class="t s3_186">MS-45 </span>
<span id="tb_186" class="t s4_186">published in 2009 showed that surgery or RT have similar effectiveness </span>
<span id="tc_186" class="t s5_186">573 </span>
<span id="td_186" class="t s4_186">(see </span><span id="te_186" class="t s6_186">Cancer of the Glottic Larynx </span><span id="tf_186" class="t s4_186">and </span><span id="tg_186" class="t s6_186">Cancer of the Supraglottic Larynx </span><span id="th_186" class="t s4_186">in </span>
<span id="ti_186" class="t s4_186">the NCCN Guidelines for Head and Neck Cancers), although the quality of </span>
<span id="tj_186" class="t s4_186">studies comparing the effectiveness of RT and surgery in early laryngeal </span>
<span id="tk_186" class="t s4_186">cancer is low. </span>
<span id="tl_186" class="t s5_186">574 </span>
<span id="tm_186" class="t s4_186">A systematic review including 48 studies of patients with </span>
<span id="tn_186" class="t s4_186">T2 glottic cancer specifically showed no difference in 5-year local control </span>
<span id="to_186" class="t s4_186">between transoral surgery (1156 patients; 77.3%) and EBRT (3191 </span>
<span id="tp_186" class="t s4_186">patients; 75.8%). </span>
<span id="tq_186" class="t s5_186">575 </span>
<span id="tr_186" class="t s4_186">However, a meta-analysis including 11 studies </span>
<span id="ts_186" class="t s4_186">showed that OS (</span><span id="tt_186" class="t s6_186">P </span><span id="tu_186" class="t s4_186">= .04) and laryngeal preservation ( </span><span id="tv_186" class="t s6_186">P </span><span id="tw_186" class="t s4_186">&lt; .001) were both </span>
<span id="tx_186" class="t s4_186">better in patients who were treated with transoral laser microsurgery, </span>
<span id="ty_186" class="t s4_186">compared to patients treated with RT. </span>
<span id="tz_186" class="t s5_186">576 </span>
<span id="t10_186" class="t s4_186">The choice of treatment modality </span>
<span id="t11_186" class="t s4_186">depends on anticipated functional outcome, the patient’s wishes, reliability </span>
<span id="t12_186" class="t s4_186">of follow-up, and general medical condition. </span>
<span id="t13_186" class="t s5_186">577 </span>
<span id="t14_186" class="t s4_186">In patients with significant </span>
<span id="t15_186" class="t s4_186">pulmonary comorbidity, total laryngectomy may be preferable over </span>
<span id="t16_186" class="t s4_186">endoscopic or open partial laryngectomy. Partial laryngeal surgery should </span>
<span id="t17_186" class="t s4_186">be carefully considered if adjuvant RT is likely. Consideration should be </span>
<span id="t18_186" class="t s4_186">given to any suspicious lymphadenopathy and risk of metastatic nodal </span>
<span id="t19_186" class="t s4_186">disease. Neck dissection should be performed as indicated when the </span>
<span id="t1a_186" class="t s4_186">primary site is treated surgically. In patients with T1–2 node-negative </span>
<span id="t1b_186" class="t s4_186">cancer of the supraglottic larynx, lymph node dissection is associated with </span>
<span id="t1c_186" class="t s4_186">greater OS. </span>
<span id="t1d_186" class="t s5_186">578 </span>
<span id="t1e_186" class="t s4_186">T1–2 supraglottic cancers have a significant risk of occult </span>
<span id="t1f_186" class="t s4_186">nodal disease at presentation. </span>
<span id="t1g_186" class="t s4_186">Postoperative adjuvant treatment depends on the presence or absence of </span>
<span id="t1h_186" class="t s4_186">adverse pathologic features, such as margin status, nodal staging, and </span>
<span id="t1i_186" class="t s4_186">any extranodal extension. For cancer of the glottic larynx, subglottic </span>
<span id="t1j_186" class="t s4_186">extension is also considered an adverse pathologic feature. In the event of </span>
<span id="t1k_186" class="t s4_186">close or positive margins in organ preservation surgery, re-resection to </span>
<span id="t1l_186" class="t s4_186">negative margins may be considered. This may or may not require a total </span>
<span id="t1m_186" class="t s4_186">laryngectomy to achieve. </span>
<span id="t1n_186" class="t s4_186">Resectable, advanced-stage glottic and supraglottic primaries are usually </span>
<span id="t1o_186" class="t s4_186">managed with a combined modality approach (see </span><span id="t1p_186" class="t s6_186">Cancer of the Glottic </span>
<span id="t1q_186" class="t s6_186">Larynx </span><span id="t1r_186" class="t s4_186">and </span><span id="t1s_186" class="t s6_186">Cancer of the Supraglottic Larynx </span><span id="t1t_186" class="t s4_186">in the NCCN Guidelines for </span>
<span id="t1u_186" class="t s4_186">Head and Neck Cancers). If laryngeal preservation is desired, concurrent </span>
<span id="t1v_186" class="t s4_186">systemic therapy/RT is recommended, based on results from Intergroup </span>
<span id="t1w_186" class="t s4_186">trial RTOG 91-11. </span>
<span id="t1x_186" class="t s5_186">288,294 </span>
<span id="t1y_186" class="t s4_186">R91-11 was a successor trial to the VA trial and </span>
<span id="t1z_186" class="t s4_186">compared three non-surgical regimens: 1) induction cisplatin/5-FU </span>
<span id="t20_186" class="t s4_186">followed by RT (control arm and identical to that in the VA trial); 2) </span>
<span id="t21_186" class="t s4_186">concurrent RT and high-dose cisplatin 100 mg/m </span>
<span id="t22_186" class="t s5_186">2 </span>
<span id="t23_186" class="t s4_186">days 1, 22, and 43; and </span>
<span id="t24_186" class="t s4_186">3) RT alone. RT was uniform in all three arms (70 Gy/7 weeks, 2 </span>
<span id="t25_186" class="t s4_186">Gy/fraction), as was the option of surgery (including total laryngectomy) for </span>
<span id="t26_186" class="t s4_186">relapsed/refractory disease in all arms. Patients with stage III and IV (M0) </span>
<span id="t27_186" class="t s4_186">disease were eligible, excluding T1 primaries and high-volume T4 </span>
<span id="t28_186" class="t s4_186">primaries (tumor extending &gt;1 cm into the base of the tongue or tumor </span>
<span id="t29_186" class="t s4_186">penetrating through cartilage). The key findings of the R91-11 trial were: 1) </span>
<span id="t2a_186" class="t s4_186">a statistically significant higher 2-year laryngeal preservation (local control) </span>
<span id="t2b_186" class="t s4_186">rate of 88% for concurrent RT with cisplatin, compared to 74% for </span>
<span id="t2c_186" class="t s4_186">induction chemotherapy and 69% for RT alone; 2) no significant difference </span>
<span id="t2d_186" class="t s4_186">in laryngeal preservation between induction and RT alone treatments; and </span>
<span id="t2e_186" class="t s4_186">3) similar survival for all treatment groups. Based on these results, </span>
<span id="t2f_186" class="t s4_186">concurrent RT and systemic therapy (cisplatin preferred [category 1]) is a </span>
<span id="t2g_186" class="t s4_186">treatment option for achieving laryngeal preservation for T3, any N glottic </span>
<span id="t2h_186" class="t s4_186">and supraglottic cancers. </span>
<span id="t2i_186" class="t s5_186">294 </span>
<span id="t2j_186" class="t s4_186">Long-term follow-up (10 years) of R91-11 </span>
<span id="t2k_186" class="t s4_186">indicates that laryngeal preservation continues to be better (ie, statistically </span>
<span id="t2l_186" class="t s4_186">different) with concurrent cisplatin/RT when compared with either induction </span>
<span id="t2m_186" class="t s4_186">chemotherapy or RT alone. </span>
<span id="t2n_186" class="t s5_186">288 </span>
<span id="t2o_186" class="t s4_186">OS was not statistically different for all </span>
<span id="t2p_186" class="t s4_186">treatment groups; there was more non–cancer-related mortality among </span>
<span id="t2q_186" class="t s4_186">patients treated with concurrent cisplatin/RT. </span>
<span id="t2r_186" class="t s4_186">Definitive RT (without systemic therapy) is an option for patients with T3, </span>
<span id="t2s_186" class="t s4_186">N0–1 disease who are medically unfit or refuse systemic therapy (see </span>
<span id="t2t_186" class="t s6_186">Cancer of the Glottic Larynx </span><span id="t2u_186" class="t s4_186">and </span><span id="t2v_186" class="t s6_186">Cancer of the Supraglottic Larynx </span><span id="t2w_186" class="t s4_186">in the </span>
<span id="t2x_186" class="t s7_186">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
